Other · Immune activation, directed at nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and toll-like receptor 9 (TLR9) · developed by Innate Immunotherapeutics
MIS416 is a microparticle combining muramyl dipeptide and bacterial-derived DNA fragments from Propionibacterium acnes. It is taken up by monocytes and dendritic cells, where it binds and activates the innate pattern recognition receptors NOD2 and TLR9, stimulating cytokine and interferon secretion and immune cell activity. It is studied in secondary progressive multiple sclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02228213 | Phase 2 | Secondary Progressive Multiple Sclerosis | Completed | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Secondary Progressive Multiple Sclerosis
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →